← Leaderboards
John Dashe
Beth Israel Deaconess Medical Center
$775,664
Attributed
$775,664
Total exposure
3
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$775,664 · 3
By mechanism
M01$775,664 · 3
Top collaborators
No co-investigators on record.
Most similar at Beth Israel Deaconess Medical Center
Same institution · by research overlap
- David K. Simon$9,625,206
- Michael William Donnino$9,108,770
- Sarinnapha Vasunilashorn$3,257,145
- Rajiv R Ratan$2,742,688
- Magdy H Selim$25,483,621
Others in their field
Top investigators on “Drug Screening /Evaluation”
- Fred M Gordin · Social And Scientific Systems, Inc.$68,001,399
- John C S Breitner · Johns Hopkins University$33,065,187
- Philip J Disaia · University Of California Irvine$21,551,991
- George R Painter · Chimerix, Inc.$19,230,662
- Gregory H Reaman · National Childhood Cancer Foundation$17,052,970
- Stephen J Durako · Westat, Inc.$15,048,684
Research focus
Drug Screening /EvaluationHuman Therapy EvaluationHuman SubjectClinical ResearchNeuroprotectantsClinical Trial Phase IAcute Disease /DisorderIntravenous AdministrationPharmacokineticsStroke TherapyCardiovascular AgentsInhibitor /AntagonistSensory NeuropathyIschemiaMedical ComplicationNervous System Disorder ChemotherapyAids /Hiv NeuropathyNeurotrophic FactorsStrokeRecombinant ProteinsGlycineHiv InfectionsCardiovascular Disorder Chemotherapy
Grant awards (9)
STUDY OF NPS 1506 ADMINISTERED INTRAVENOUSLY TO SUBJECTS WITH ACUTE STROKE$0
M01 · FY2002 · RR
STUDY OF NPS 1506 ADMINISTERED INTRAVENOUSLY TO SUBJECTS WITH ACUTE STROKE$0
M01 · FY2001 · RR
GLYSINE ANTAGONIST IN NEUROPROTECTION (GAIN) ACUTE STROKE STUDY$193,916
M01 · FY2000 · RR
ACTG 291--RECOMBINANT HUMAN NGF FOR HIV ASSOCIATED SENSORY NEUROPATHY$193,916
M01 · FY2000 · RR
ACTG 291--RECOMBINANT HUMAN NGF FOR HIV ASSOCIATED SENSORY NEUROPATHY$193,916
M01 · FY2000 · RR
GLYSINE ANTAGONIST IN NEUROPROTECTION (GAIN) ACUTE STROKE STUDY$193,916
M01 · FY2000 · RR
STUDY OF NPS 1506 ADMINISTERED INTRAVENOUSLY TO SUBJECTS WITH ACUTE STROKE$0
M01 · FY2000 · RR
STUDY OF NPS 1506 ADMINISTERED INTRAVENOUSLY TO SUBJECTS WITH ACUTE STROKE$0
M01 · FY2000 · RR
STUDY OF NPS 1506 ADMINISTERED INTRAVENOUSLY TO SUBJECTS WITH ACUTE STROKE$0
M01 · FY2000 · RR